Author

Wendy Magis

UCSF Benioff Children's Hospital

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Genetics· 2 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Assay:CRISPR screen· 2 Approach:experimental assay· 2 Research Focus:gene regulatory network inference· 1 Approach:genetic perturbation / CRISPR· 1 Research Focus:variant calling· 1

Frequent Co-Authors

Jacob E. CorniD· 3 shared Mark A. DeWittiD· 3 shared Mark C. WaltersiD· 3 shared Dario BoffelliiD· 2 shared David I. K. Martin· 2 shared Donald B. KohniD· 2 shared Jonathan T. VuiD· 2 shared Seok‐Jin HeoiD· 2 shared

Activity by Year

2016-2019 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 40 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersGenetics

Jacob E. CornORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

CRISPR-Cas9 interrogation of a putative fetal globin repressor in human erythroid cells.

Jennifer E. Chung, Wendy Magis, Jonathan T. Vu, Seok‐Jin Heo, Kirmo Wartiovaara, Mark C. Walters, Ryo Kurita, Yukio Nakamura, Dario Boffelli, David I. K. Martin, Jacob E. Corn, Mark A. DeWitt

This study uses CRISPR-Cas9 to test a putative fetal globin repressor region, finding it does not autonomously silence gamma-globin, suggesting it is not a therapeutic target for beta-hemoglobinopathies.

PLoS ONE · Jan 15, 2019Peer-reviewedGenetics

High-level correction of the sickle mutation amplified in vivo during erythroid differentiation

Wendy Magis, Mark A. DeWitt, Stacia K. Wyman, Jonathan T. Vu, Seok‐Jin Heo, Shirley J. Shao, Fiona Hennig, Zulema G. Romero, Beatriz Campo-Fernández, Matthew McNeill, Garrett R. Rettig, Yongming Andrew Sun, Patrick J. Lau, Yu Wang, Mark A. Behlke, , David I. K. Martin

Cas9-mediated correction of the sickle mutation in human hematopoietic stem cells achieves curative levels of editing.

bioRxiv · Jan 8, 2019 · PreprintGenetics

Efficient Correction of the Sickle Mutation in Human Hematopoietic Stem Cells Using a Cas9 Ribonucleoprotein Complex

Mark A. DeWitt, Wendy Magis, Nicolas L. Bray, Tianjiao Wang, Jennifer R. Berman, Fabrizia Urbinati, Denise P. Muñoz, Donald B. Kohn, Mark C. Walters, Dana Carroll, David K. Martin, Jacob E. Corn

This study corrects the sickle mutation in human hematopoietic stem cells using a Cas9 RNP/ssDNA donor approach, showing long-term therapeutic editing in mice.

bioRxiv · Jan 15, 2016 · PreprintCell Biology